EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns

September 20, 2022

https://www.globenewswire.com/news-release/2022/09/20/2519055/30505/en/EMA-Accepts-MediWound-s-Application-for-Extended-Indication-for-NexoBrid-to-Treat-Pediatric-Patients-with-Severe-Thermal-Burns.html

YAVNE, Israel, Sept. 20, 2022 (GLOBE NEWSWIRE) — MediWound Ltd. (NASDAQ:MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the European Medicines Agency (EMA) has validated for review the Type II Variation submitted by MediWound in order to expand the current approved indication for NexoBrid (removal of eschar in adults with deep partial-and full-thickness thermal burn wounds) into the pediatric population. MediWound expects a decision from the European Commission in the first quarter of 2023.

Read more at globenewswire.com

Related news for (MDWD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.